Gene Therapy Market by Type (Gene silencing), Vector (Viral (Retroviral, AAV), Non-viral (Oligonucleotide)), Gene Type (Receptors, Cytokine), Therapeutic Area (Oncology, Neurology), Delivery Method (In-Vivo, Ex-Vivo), RoA (IV) - Global Forecast to 2032
The global gene therapy market is projected to reach USD 36.55 billion by 2032 from USD 8.85 billion in 2024, at a CAGR of 19.4% during the forecast period of 2024 to 2032. The growth of the gene therapy market has been significantly driven by increasing R&D investment by key players for the development gene therapy drugs and growing approval of novel gene therapies. However, complex regulatory frameworks and ethical concerns regarding genetic modifications are restraining market growth.
“The intravenous route segment accounted for the largest share by route of administration in 2023.”
Based on route of administration, the gene therapy market is segmented into intravenous route, subcutaneous route and other routes. The intravenous route segment accounted for the largest share of the gene therapy market in 2023. The larger share of this segment is mainly attributed to the number of gene therapy administered through intravenous route is due to factors such as the high effectiveness of intravenous administration and high penetration of intravenous gene therapy currently approved and marketed products among others.
“The US has continued to dominate the gene therapy market during the forecast period of 2024-2032.”
The US is the world’s largest biopharmaceutical market and a leader in biopharmaceutical research/investments. Driven by the growing patient population suffering from chronid disease, increasing biopharmaceuticals' importance, and the necessity of safe and high-quality products in the healthcare sector, growing investments and funding in biomedical research by government bodies and pharmaceutical & biotechnology companies. Also, a strong established presence of several market players in the region is another key factor supporting market growth. These key companies include, Biogen Inc. (US), Alnylam Pharmaceuticals, Inc. (US), and Sarepta Therapeutics, Inc. (US).
The primary interviews conducted for this report can be categorized as follows:
Biogen Inc. (US), Novartis AG (Switzerland), Alnylam Pharmaceuticals, Inc. (US), Sarepta Therapeutics, Inc. (US), Jazz Pharmaceuticals Plc (Ireland), Ferring B.V. (Switzerland), Pfizer Inc. (US), Amgen, Inc. (US), Johnson & Johnson Services, Inc. (US), Daiichi Sankyo Company, Limited. (Japan), BioMarin Pharmaceutical Inc. (US), Kyowa Kirin Co., Ltd. (Japan), Nippon Shinyaku Co., Ltd. (Japan), PTC Therapeutics (US), UniQure NV (Netherlands), Juventas Cell Therapy Ltd. (China), CRISPR Therapeutics (Switzerland), bluebird bio, Inc. (US), Krystal Biotech, Inc. (US), Shanghai Sunway Biotech Co., Ltd. (China), JW (Cayman) Therapeutics Co. Ltd (China), IASO Biotechnology (China), CARsgen Therapeutics Holdings Limited (China), Adaptimmune (UK), Sibiono GeneTech Co. Ltd. (China), and Ultragenyx Pharmaceutical Inc. (US).
Research Coverage:
This research report categorizes the gene therapy market by Therapy Type (Gene Silencing Therapy, Cell Replacement Therapy, Gene Augmentation Therapy and Other Therapies)), by Vector (Viral Vectors (Retroviral Vector (Gamma retroviral vectors, Lentiviral Vectors) AAV Vectors, and Other Viral Vectors), Non-viral Vectors (Oligonucleotides and Other Non-viral Vectors)), by Gene Type (Deficiency, Receptors, Antigen, Cytokine, Tumor Suppressor, and Othe Genes), by Therapeutic Area (Neurology, Oncology, Hematology and Other Therapeutic Areas), by Delivery Method (In Vivo and Ex Vivo), by Route of Administration (Intravenous Route, Subcutaneous Route, and Other Routes), by End User (Hospitals, Specialty Centers, and Other End Users) and by region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the oral proteins and peptides market. A detailed analysis of the key industry players has been done to provide insights into their business overview, products, solutions, key strategies, collaborations, partnerships, and agreements. New approvals/launches, collaborations and acquisitions, and recent developments associated with the gene therapy market.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall gene therapy market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
“The intravenous route segment accounted for the largest share by route of administration in 2023.”
Based on route of administration, the gene therapy market is segmented into intravenous route, subcutaneous route and other routes. The intravenous route segment accounted for the largest share of the gene therapy market in 2023. The larger share of this segment is mainly attributed to the number of gene therapy administered through intravenous route is due to factors such as the high effectiveness of intravenous administration and high penetration of intravenous gene therapy currently approved and marketed products among others.
“The US has continued to dominate the gene therapy market during the forecast period of 2024-2032.”
The US is the world’s largest biopharmaceutical market and a leader in biopharmaceutical research/investments. Driven by the growing patient population suffering from chronid disease, increasing biopharmaceuticals' importance, and the necessity of safe and high-quality products in the healthcare sector, growing investments and funding in biomedical research by government bodies and pharmaceutical & biotechnology companies. Also, a strong established presence of several market players in the region is another key factor supporting market growth. These key companies include, Biogen Inc. (US), Alnylam Pharmaceuticals, Inc. (US), and Sarepta Therapeutics, Inc. (US).
The primary interviews conducted for this report can be categorized as follows:
- By Respondent: Supply Side- 70% and Demand Side 30%
- By Designation: Managers - 45%, CXO & Directors - 30%, and Executives - 25%
- By Region: North America -40%, Europe -25%, Asia-Pacific -25%, Latin America -5% and Middle East & Africa- 5%
Biogen Inc. (US), Novartis AG (Switzerland), Alnylam Pharmaceuticals, Inc. (US), Sarepta Therapeutics, Inc. (US), Jazz Pharmaceuticals Plc (Ireland), Ferring B.V. (Switzerland), Pfizer Inc. (US), Amgen, Inc. (US), Johnson & Johnson Services, Inc. (US), Daiichi Sankyo Company, Limited. (Japan), BioMarin Pharmaceutical Inc. (US), Kyowa Kirin Co., Ltd. (Japan), Nippon Shinyaku Co., Ltd. (Japan), PTC Therapeutics (US), UniQure NV (Netherlands), Juventas Cell Therapy Ltd. (China), CRISPR Therapeutics (Switzerland), bluebird bio, Inc. (US), Krystal Biotech, Inc. (US), Shanghai Sunway Biotech Co., Ltd. (China), JW (Cayman) Therapeutics Co. Ltd (China), IASO Biotechnology (China), CARsgen Therapeutics Holdings Limited (China), Adaptimmune (UK), Sibiono GeneTech Co. Ltd. (China), and Ultragenyx Pharmaceutical Inc. (US).
Research Coverage:
This research report categorizes the gene therapy market by Therapy Type (Gene Silencing Therapy, Cell Replacement Therapy, Gene Augmentation Therapy and Other Therapies)), by Vector (Viral Vectors (Retroviral Vector (Gamma retroviral vectors, Lentiviral Vectors) AAV Vectors, and Other Viral Vectors), Non-viral Vectors (Oligonucleotides and Other Non-viral Vectors)), by Gene Type (Deficiency, Receptors, Antigen, Cytokine, Tumor Suppressor, and Othe Genes), by Therapeutic Area (Neurology, Oncology, Hematology and Other Therapeutic Areas), by Delivery Method (In Vivo and Ex Vivo), by Route of Administration (Intravenous Route, Subcutaneous Route, and Other Routes), by End User (Hospitals, Specialty Centers, and Other End Users) and by region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the oral proteins and peptides market. A detailed analysis of the key industry players has been done to provide insights into their business overview, products, solutions, key strategies, collaborations, partnerships, and agreements. New approvals/launches, collaborations and acquisitions, and recent developments associated with the gene therapy market.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall gene therapy market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
- Analysis of key drivers (Growing demand for curative therapies for genetic disorders, rare diseases, and specific types of cancer, Increasing investments in gene therapy research, Growing technological advancements, and Robust clinical trial pipeline for gene therapy), restraints (High cost of gene therapy products, Complex regulatory frameworks and ethical concerns regarding genetic modifications, and Limited manufacturing scalability), opportunities (Expansion into rare diseases and unmet needs, Increasing focus on precision medicine, and Advancements in gene therapy delivery technologies), and Challenges (Complex manufacturing process, Short shelf life and supply chain challenges, and Lack of reimbursement).
- Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and new product approvals/launches in the gene therapy market.
- Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the gene therapy market
- Competitive Assessment: In-depth assessment of market shares, growth strategies and product offerings of leading players. A detailed analysis of the key industry players has been done to provide insights into their key strategies, product launches/ approvals, pipeline analysis, acquisitions, partnerships, agreements, collaborations, other recent developments, investment and funding activities, brand/product comparative analysis, and vendor valuation and financial metrics of the gene therapy market.
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKETS COVERED & REGIONAL SEGMENTATION
1.3.2 INCLUSIONS & EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.3.4 CURRENCY CONSIDERED
1.4 STAKEHOLDERS
1.5 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY RESEARCH
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY RESEARCH
2.1.2.1 Insights of primary experts
2.2 MARKET SIZE ESTIMATION
2.2.1 GLOBAL MARKET ESTIMATION
2.2.2 SEGMENTAL MARKET SIZE ESTIMATION
2.3 MARKET GROWTH RATE PROJECTIONS
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
2.5 RESEARCH ASSUMPTIONS
2.6 RESEARCH LIMITATIONS
2.7 RISK ANALYSIS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 GENE THERAPY MARKET OVERVIEW
4.2 NORTH AMERICA: GENE THERAPY MARKET, BY THERAPY TYPE & COUNTRY (2024)
4.3 GENE THERAPY MARKET SHARE, BY END USER, 2024 VS 2032
4.4 GENE THERAPY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Growing demand for curative therapies for genetic disorders, rare diseases, and cancers
5.2.1.2 Increasing investments in gene therapy research
5.2.1.3 Technological advancements
5.2.1.4 Robust clinical trial pipeline for gene therapy
5.2.2 RESTRAINTS
5.2.2.1 High cost of gene therapy products
5.2.2.2 Complex regulatory frameworks and ethical concerns regarding genetic modifications
5.2.2.3 Limited manufacturing scalability
5.2.3 OPPORTUNITIES
5.2.3.1 Expansion into rare diseases and unmet needs
5.2.3.2 Increasing focus on precision medicine
5.2.3.3 Advancements in gene therapy delivery technologies
5.2.4 CHALLENGES
5.2.4.1 Complex commercial manufacturing and scaling process
5.2.4.2 Short shelf life and supply chain challenges
5.2.4.3 Lack of reimbursement
5.3 TECHNOLOGY ANALYSIS
5.3.1 KEY TECHNOLOGIES
5.3.1.1 CRISPR-Cas9
5.3.1.2 RNA interference
5.3.1.3 Viral vectors
5.3.2 COMPLEMENTARY TECHNOLOGIES
5.3.2.1 Stem cell therapy
5.3.2.2 Omics technologies
5.3.3 ADJACENT TECHNOLOGIES
5.3.3.1 Nanoparticles
5.4 VALUE CHAIN ANALYSIS
5.5 SUPPLY CHAIN ANALYSIS
5.5.1 PROMINENT COMPANIES
5.5.2 SMALL AND MEDIUM-SIZED ENTERPRISES
5.5.3 END USERS
5.5.4 INVESTORS, VENTURE CAPITALISTS, AND FUNDING BODIES
5.5.5 REGULATORY BODIES
5.6 ECOSYSTEM ANALYSIS
5.7 PATENT ANALYSIS
5.8 PIPELINE ANALYSIS
5.9 REGULATORY LANDSCAPE
5.9.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS, BY REGION
5.9.2 REGULATORY FRAMEWORK
5.9.3 REIMBURSEMENT SCENARIO
5.10 PRICING ANALYSIS
5.10.1 AVERAGE SELLING PRICE TREND, BY KEY PLAYER
5.10.2 AVERAGE SELLING PRICE TREND, BY REGION
5.11 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.12 KEY CONFERENCES & EVENTS, 2025–2026
5.13 PORTER’S FIVE FORCES ANALYSIS
5.13.1 THREAT OF NEW ENTRANTS
5.13.2 THREAT OF SUBSTITUTES
5.13.3 BARGAINING POWER OF SUPPLIERS
5.13.4 BARGAINING POWER OF BUYERS
5.13.5 INTENSITY OF COMPETITIVE RIVALRY
5.14 KEY STAKEHOLDERS & BUYING CRITERIA
5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
5.14.2 BUYING CRITERIA
5.15 INVESTMENT & FUNDING SCENARIO
5.16 IMPACT OF AI ON GENE THERAPY MARKET
6 GENE THERAPY MARKET, BY THERAPY TYPE
6.1 INTRODUCTION
6.2 GENE SILENCING THERAPY
6.2.1 FLEXIBILITY AND PRECISION OF GENE SILENCING THERAPIES TO SUPPORT GROWTH
6.3 CELL REPLACEMENT THERAPY
6.3.1 LONG-TERM EFFECT OF THERAPY TO SUPPORT GROWTH IN ADOPTION
6.4 GENE AUGMENTATION THERAPY
6.4.1 EFFECTIVENESS AGAINST MONOGENIC DISORDERS TO DRIVE MARKET
6.5 OTHER THERAPIES
7 GENE THERAPY MARKET, BY VECTOR
7.1 INTRODUCTION
7.2 VIRAL VECTORS
7.2.1 RETROVIRAL VECTORS
7.2.1.1 Advantages of retroviral vectors to support market growth
7.2.1.2 Gamma-retroviral vectors
7.2.1.2.1 Availability of gamma-retroviral vectors to support market growth
7.2.1.3 Lentiviral vectors
7.2.1.3.1 North America to dominate lentiviral vectors market
7.2.2 AAV VECTORS
7.2.2.1 Focus of clinical pipeline on adeno-associated viral vectors to drive growth
7.2.3 OTHER VIRAL VECTORS
7.3 NON-VIRAL VECTORS
7.3.1 OLIGONUCLEOTIDE VECTORS
7.3.1.1 Oligonucleotides to account for largest share of non-viral vectors market
7.3.2 OTHER NON-VIRAL VECTORS
8 GENE THERAPY MARKET, BY GENE TYPE
8.1 INTRODUCTION
8.2 DEFICIENCY
8.2.1 TECHNOLOGICAL ADVANCEMENT IN GENE THERAPIES TO BOOST GROWTH
8.3 RECEPTOR
8.3.1 INCREASING DEMAND FOR DEVELOPING RECEPTOR-BASED GENE THERAPY TO SUPPORT MARKET GROWTH
8.4 ANTIGEN
8.4.1 INCREASING DEMAND FOR TARGETED THERAPIES TO PROPEL GROWTH
8.5 CYTOKINE
8.5.1 RISING R&D TO SUPPORT MARKET GROWTH
8.6 TUMOR SUPPRESSOR
8.6.1 RISING PREVALENCE OF CANCER TO PROPEL MARKET GROWTH
8.7 OTHER GENES
9 GENE THERAPY MARKET, BY THERAPEUTIC AREA
9.1 INTRODUCTION
9.2 NEUROLOGY
9.2.1 ENHANCED DELIVERY METHODS AND ADVANCEMENTS IN GENE EDITING TECHNOLOGIES TO BOOST MARKET GROWTH
9.3 ONCOLOGY
9.3.1 RISING BURDEN OF CANCER TO SUPPORT MARKET GROWTH
9.4 HEMATOLOGY
9.4.1 INCREASING PREVALENCE OF GENETIC BLOOD DISORDERS TO BOOST MARKET GROWTH
9.5 OTHER THERAPEUTIC AREAS
10 GENE THERAPY MARKET, BY DELIVERY METHOD
10.1 INTRODUCTION
10.2 IN VIVO DELIVERY
10.2.1 IN VIVO DELIVERY METHOD TO ACCOUNT FOR LARGEST MARKET SHARE IN 2023
10.3 EX VIVO DELIVERY
10.3.1 GROWING FOCUS ON ONCOLOGY THERAPEUTICS TO SUPPORT MARKET GROWTH
11 GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION
11.1 INTRODUCTION
11.2 INTRAVENOUS ROUTE
11.2.1 HIGH EFFECTIVENESS AND LARGE SHARE OF INTRAVENOUS PRODUCTS TO SUPPORT MARKET GROWTH
11.3 SUBCUTANEOUS ROUTE
11.3.1 DEVELOPMENT OF IMPROVED DELIVERY DEVICES TO SUPPORT MARKET GROWTH
11.4 OTHER ROUTES
12 GENE THERAPY MARKET, BY END USER
12.1 INTRODUCTION
12.2 HOSPITALS
12.2.1 GROWING DEMAND FOR ADVANCED THERAPIES TO BOOST MARKET
12.3 SPECIALTY CENTERS
12.3.1 ADVANCEMENTS IN GENE THERAPY TECHNOLOGIES TO SUPPORT MARKET GROWTH
12.4 OTHER END USERS
13 GENE THERAPY MARKET, BY REGION
13.1 INTRODUCTION
13.2 NORTH AMERICA
13.2.1 NORTH AMERICA: MACROECONOMIC ANALYSIS
13.2.2 US
13.2.2.1 US to dominate North American market during forecast period
13.2.3 CANADA
13.2.3.1 Government support for expanding manufacturing facilities to propel market growth
13.3 EUROPE
13.3.1 EUROPE: MACROECONOMIC ANALYSIS
13.3.2 GERMANY
13.3.2.1 Growing pharmaceutical R&D and manufacturing to drive market
13.3.3 UK
13.3.3.1 Strong government support to propel market growth
13.3.4 FRANCE
13.3.4.1 Government investment in pharmaceutical industry to drive growth
13.3.5 ITALY
13.3.5.1 Initiatives for gene therapy development to drive growth
13.3.6 SPAIN
13.3.6.1 Expansion of biomanufacturing facilities to support market growth
13.3.7 SWITZERLAND
13.3.7.1 Presence of key pharmaceutical and biopharmaceutical companies to support market growth
13.3.8 NETHERLANDS
13.3.8.1 Growing awareness and strong focus on pharmaceutical R&D to support market growth
13.3.9 REST OF EUROPE
13.4 ASIA PACIFIC
13.4.1 ASIA PACIFIC: MACROECONOMIC ANALYSIS
13.4.2 CHINA
13.4.2.1 China to dominate Asia Pacific market during forecast period
13.4.3 JAPAN
13.4.3.1 Increasing initiatives supporting gene therapy adoption to propel market growth
13.4.4 INDIA
13.4.4.1 Favorable scenario for foreign direct investment to favor market growth
13.4.5 AUSTRALIA
13.4.5.1 Increasing demand for innovative therapies to propel market
13.4.6 SOUTH KOREA
13.4.6.1 Increased export of drugs to support market growth
13.4.7 THAILAND
13.4.7.1 Favorable government policies to propel adoption of advanced therapies
13.4.8 REST OF ASIA PACIFIC
13.5 LATIN AMERICA
13.5.1 LATIN AMERICA: MACROECONOMIC ANALYSIS
13.5.2 BRAZIL
13.5.2.1 Brazil to dominate LATAM market during forecast period
13.5.3 MEXICO
13.5.3.1 Rising demand for chronic disease treatment to support market growth
13.5.4 REST OF LATIN AMERICA
13.6 MIDDLE EAST
13.6.1 MIDDLE EAST: MACROECONOMIC ANALYSIS
13.6.2 GCC COUNTRIES
13.6.2.1 Saudi Arabia
13.6.2.1.1 Growing healthcare expenditure to boost market growth
13.6.2.2 UAE
13.6.2.2.1 Growing focus on genetic medicine development projects to drive market
13.6.2.3 Rest of GCC Countries
13.6.3 REST OF MIDDLE EAST
13.7 AFRICA
13.7.1 HIGH GROWTH POTENTIAL OF AFRICAN MARKETS TO ATTRACT KEY PLAYERS
13.7.2 AFRICA: MACROECONOMIC ANALYSIS
14 COMPETITIVE LANDSCAPE
14.1 OVERVIEW
14.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2022–2024
14.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN GENE THERAPY MARKET, 2022?2024
14.3 REVENUE ANALYSIS, 2021–2023
14.4 MARKET SHARE ANALYSIS, 2023
14.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
14.5.1 STARS
14.5.2 EMERGING LEADERS
14.5.3 PERVASIVE PLAYERS
14.5.4 PARTICIPANTS
14.5.5 COMPETITIVE BENCHMARKING: KEY PLAYERS, 2023
14.5.5.1 Company footprint
14.5.5.2 Region footprint
14.5.5.3 Therapy type footprint
14.5.5.4 Therapeutic area footprint
14.5.5.5 Route of administration footprint
14.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
14.6.1 PROGRESSIVE COMPANIES
14.6.2 RESPONSIVE COMPANIES
14.6.3 DYNAMIC COMPANIES
14.6.4 STARTING BLOCKS
14.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
14.6.5.1 Detailed list of key startups/SMEs
14.6.5.2 Competitive benchmarking of key startups/SMEs
14.7 VALUATION & FINANCIAL METRICS
14.7.1 FINANCIAL METRICS
14.7.2 COMPANY VALUATION
14.8 BRAND/PRODUCT COMPARISON
14.9 COMPETITIVE SCENARIO
14.9.1 PRODUCT APPROVALS
14.9.2 DEALS
14.9.3 EXPANSIONS
15 COMPANY PROFILES
15.1 INTRODUCTION
15.2 KEY PLAYERS
15.2.1 BIOGEN INC.
15.2.1.1 Business overview
15.2.1.2 Products offered
15.2.1.3 Recent developments
15.2.1.3.1 Deals
15.2.1.4 MnM view
15.2.1.4.1 Key strengths
15.2.1.4.2 Strategic choices
15.2.1.4.3 Weaknesses and competitive threats
15.2.2 NOVARTIS AG
15.2.2.1 Business overview
15.2.2.2 Products offered
15.2.2.3 Recent developments
15.2.2.3.1 Deals
15.2.2.3.2 Expansions
15.2.2.3.3 Other developments
15.2.2.4 MnM view
15.2.2.4.1 Key strengths
15.2.2.4.2 Strategic choices
15.2.2.4.3 Weaknesses and competitive threats
15.2.3 ALNYLAM PHARMACEUTICALS, INC.
15.2.3.1 Business overview
15.2.3.2 Products offered
15.2.3.3 Recent developments
15.2.3.3.1 Product approvals
15.2.3.3.2 Deals
15.2.3.3.3 Other developments
15.2.3.4 MnM view
15.2.3.4.1 Key strengths
15.2.3.4.2 Strategic choices
15.2.3.4.3 Weaknesses and competitive threats
15.2.4 SAREPTA THERAPEUTICS, INC.
15.2.4.1 Business overview
15.2.4.2 Products offered
15.2.4.3 Recent developments
15.2.4.3.1 Product approvals
15.2.4.3.2 Deals
15.2.4.4 MnM view
15.2.4.4.1 Key strengths
15.2.4.4.2 Strategic choices
15.2.4.4.3 Weaknesses and competitive threats
15.2.5 JAZZ PHARMACEUTICALS PLC
15.2.5.1 Business overview
15.2.5.2 Products offered
15.2.5.3 Recent developments
15.2.5.3.1 Expansions
15.2.5.4 MnM view
15.2.5.4.1 Key strengths
15.2.5.4.2 Strategic choices
15.2.5.4.3 Weaknesses and competitive threats
15.2.6 FERRING B.V.
15.2.6.1 Business overview
15.2.6.2 Products offered
15.2.6.3 Recent developments
15.2.6.3.1 Product approvals
15.2.6.3.2 Deals
15.2.6.3.3 Expansions
15.2.7 PFIZER INC.
15.2.7.1 Business overview
15.2.7.2 Products offered
15.2.7.3 Recent developments
15.2.7.3.1 Product approvals
15.2.7.3.2 Deals
15.2.8 AMGEN, INC.
15.2.8.1 Business overview
15.2.8.2 Products offered
15.2.8.3 Recent developments
15.2.8.3.1 Deals
15.2.8.3.2 Expansions
15.2.9 JOHNSON & JOHNSON SERVICES, INC.
15.2.9.1 Business overview
15.2.9.2 Products offered
15.2.9.3 Recent developments
15.2.9.3.1 Deals
15.2.9.3.2 Other developments
15.2.10 DAIICHI SANKYO COMPANY, LIMITED.
15.2.10.1 Business overview
15.2.10.2 Products offered
15.2.11 BIOMARIN PHARMACEUTICAL INC.
15.2.11.1 Business overview
15.2.11.2 Products offered
15.2.11.3 Recent developments
15.2.11.3.1 Product approvals
15.2.11.3.2 Expansions
15.2.12 KYOWA KIRIN CO., LTD.
15.2.12.1 Business overview
15.2.12.2 Products offered
15.2.12.3 Recent developments
15.2.12.3.1 Product approvals
15.2.12.3.2 Deals
15.2.13 NIPPON SHINYAKU CO., LTD.
15.2.13.1 Business overview
15.2.13.2 Products offered
15.2.13.3 Recent developments
15.2.13.3.1 Deals
15.2.14 PTC THERAPEUTICS
15.2.14.1 Business overview
15.2.14.2 Products offered
15.2.14.3 Recent developments
15.2.14.3.1 Product approvals
15.2.15 UNIQURE NV.
15.2.15.1 Business overview
15.2.15.2 Products offered
15.2.15.3 Recent developments
15.2.15.3.1 Deals
15.3 OTHER PLAYERS
15.3.1 JUVENTAS CELL THERAPY LTD.
15.3.2 CRISPR THERAPEUTICS
15.3.3 BLUEBIRD BIO, INC.
15.3.4 KRYSTAL BIOTECH, INC.
15.3.5 SHANGHAI SUNWAY BIOTECH CO., LTD.
15.3.6 JW (CAYMAN) THERAPEUTICS CO. LTD
15.3.7 IASO BIOTECHNOLOGY
15.3.8 CARSGEN THERAPEUTICS HOLDINGS LIMITED
15.3.9 ADAPTIMMUNE
15.3.10 SIBIONO GENETECH CO. LTD.
15.3.11 ULTRAGENYX PHARMACEUTICAL INC.
16 APPENDIX
16.1 DISCUSSION GUIDE
16.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
16.3 CUSTOMIZATION OPTIONS
16.4 RELATED REPORTS
16.5 AUTHOR DETAILS
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKETS COVERED & REGIONAL SEGMENTATION
1.3.2 INCLUSIONS & EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.3.4 CURRENCY CONSIDERED
1.4 STAKEHOLDERS
1.5 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY RESEARCH
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY RESEARCH
2.1.2.1 Insights of primary experts
2.2 MARKET SIZE ESTIMATION
2.2.1 GLOBAL MARKET ESTIMATION
2.2.2 SEGMENTAL MARKET SIZE ESTIMATION
2.3 MARKET GROWTH RATE PROJECTIONS
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
2.5 RESEARCH ASSUMPTIONS
2.6 RESEARCH LIMITATIONS
2.7 RISK ANALYSIS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 GENE THERAPY MARKET OVERVIEW
4.2 NORTH AMERICA: GENE THERAPY MARKET, BY THERAPY TYPE & COUNTRY (2024)
4.3 GENE THERAPY MARKET SHARE, BY END USER, 2024 VS 2032
4.4 GENE THERAPY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Growing demand for curative therapies for genetic disorders, rare diseases, and cancers
5.2.1.2 Increasing investments in gene therapy research
5.2.1.3 Technological advancements
5.2.1.4 Robust clinical trial pipeline for gene therapy
5.2.2 RESTRAINTS
5.2.2.1 High cost of gene therapy products
5.2.2.2 Complex regulatory frameworks and ethical concerns regarding genetic modifications
5.2.2.3 Limited manufacturing scalability
5.2.3 OPPORTUNITIES
5.2.3.1 Expansion into rare diseases and unmet needs
5.2.3.2 Increasing focus on precision medicine
5.2.3.3 Advancements in gene therapy delivery technologies
5.2.4 CHALLENGES
5.2.4.1 Complex commercial manufacturing and scaling process
5.2.4.2 Short shelf life and supply chain challenges
5.2.4.3 Lack of reimbursement
5.3 TECHNOLOGY ANALYSIS
5.3.1 KEY TECHNOLOGIES
5.3.1.1 CRISPR-Cas9
5.3.1.2 RNA interference
5.3.1.3 Viral vectors
5.3.2 COMPLEMENTARY TECHNOLOGIES
5.3.2.1 Stem cell therapy
5.3.2.2 Omics technologies
5.3.3 ADJACENT TECHNOLOGIES
5.3.3.1 Nanoparticles
5.4 VALUE CHAIN ANALYSIS
5.5 SUPPLY CHAIN ANALYSIS
5.5.1 PROMINENT COMPANIES
5.5.2 SMALL AND MEDIUM-SIZED ENTERPRISES
5.5.3 END USERS
5.5.4 INVESTORS, VENTURE CAPITALISTS, AND FUNDING BODIES
5.5.5 REGULATORY BODIES
5.6 ECOSYSTEM ANALYSIS
5.7 PATENT ANALYSIS
5.8 PIPELINE ANALYSIS
5.9 REGULATORY LANDSCAPE
5.9.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS, BY REGION
5.9.2 REGULATORY FRAMEWORK
5.9.3 REIMBURSEMENT SCENARIO
5.10 PRICING ANALYSIS
5.10.1 AVERAGE SELLING PRICE TREND, BY KEY PLAYER
5.10.2 AVERAGE SELLING PRICE TREND, BY REGION
5.11 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.12 KEY CONFERENCES & EVENTS, 2025–2026
5.13 PORTER’S FIVE FORCES ANALYSIS
5.13.1 THREAT OF NEW ENTRANTS
5.13.2 THREAT OF SUBSTITUTES
5.13.3 BARGAINING POWER OF SUPPLIERS
5.13.4 BARGAINING POWER OF BUYERS
5.13.5 INTENSITY OF COMPETITIVE RIVALRY
5.14 KEY STAKEHOLDERS & BUYING CRITERIA
5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
5.14.2 BUYING CRITERIA
5.15 INVESTMENT & FUNDING SCENARIO
5.16 IMPACT OF AI ON GENE THERAPY MARKET
6 GENE THERAPY MARKET, BY THERAPY TYPE
6.1 INTRODUCTION
6.2 GENE SILENCING THERAPY
6.2.1 FLEXIBILITY AND PRECISION OF GENE SILENCING THERAPIES TO SUPPORT GROWTH
6.3 CELL REPLACEMENT THERAPY
6.3.1 LONG-TERM EFFECT OF THERAPY TO SUPPORT GROWTH IN ADOPTION
6.4 GENE AUGMENTATION THERAPY
6.4.1 EFFECTIVENESS AGAINST MONOGENIC DISORDERS TO DRIVE MARKET
6.5 OTHER THERAPIES
7 GENE THERAPY MARKET, BY VECTOR
7.1 INTRODUCTION
7.2 VIRAL VECTORS
7.2.1 RETROVIRAL VECTORS
7.2.1.1 Advantages of retroviral vectors to support market growth
7.2.1.2 Gamma-retroviral vectors
7.2.1.2.1 Availability of gamma-retroviral vectors to support market growth
7.2.1.3 Lentiviral vectors
7.2.1.3.1 North America to dominate lentiviral vectors market
7.2.2 AAV VECTORS
7.2.2.1 Focus of clinical pipeline on adeno-associated viral vectors to drive growth
7.2.3 OTHER VIRAL VECTORS
7.3 NON-VIRAL VECTORS
7.3.1 OLIGONUCLEOTIDE VECTORS
7.3.1.1 Oligonucleotides to account for largest share of non-viral vectors market
7.3.2 OTHER NON-VIRAL VECTORS
8 GENE THERAPY MARKET, BY GENE TYPE
8.1 INTRODUCTION
8.2 DEFICIENCY
8.2.1 TECHNOLOGICAL ADVANCEMENT IN GENE THERAPIES TO BOOST GROWTH
8.3 RECEPTOR
8.3.1 INCREASING DEMAND FOR DEVELOPING RECEPTOR-BASED GENE THERAPY TO SUPPORT MARKET GROWTH
8.4 ANTIGEN
8.4.1 INCREASING DEMAND FOR TARGETED THERAPIES TO PROPEL GROWTH
8.5 CYTOKINE
8.5.1 RISING R&D TO SUPPORT MARKET GROWTH
8.6 TUMOR SUPPRESSOR
8.6.1 RISING PREVALENCE OF CANCER TO PROPEL MARKET GROWTH
8.7 OTHER GENES
9 GENE THERAPY MARKET, BY THERAPEUTIC AREA
9.1 INTRODUCTION
9.2 NEUROLOGY
9.2.1 ENHANCED DELIVERY METHODS AND ADVANCEMENTS IN GENE EDITING TECHNOLOGIES TO BOOST MARKET GROWTH
9.3 ONCOLOGY
9.3.1 RISING BURDEN OF CANCER TO SUPPORT MARKET GROWTH
9.4 HEMATOLOGY
9.4.1 INCREASING PREVALENCE OF GENETIC BLOOD DISORDERS TO BOOST MARKET GROWTH
9.5 OTHER THERAPEUTIC AREAS
10 GENE THERAPY MARKET, BY DELIVERY METHOD
10.1 INTRODUCTION
10.2 IN VIVO DELIVERY
10.2.1 IN VIVO DELIVERY METHOD TO ACCOUNT FOR LARGEST MARKET SHARE IN 2023
10.3 EX VIVO DELIVERY
10.3.1 GROWING FOCUS ON ONCOLOGY THERAPEUTICS TO SUPPORT MARKET GROWTH
11 GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION
11.1 INTRODUCTION
11.2 INTRAVENOUS ROUTE
11.2.1 HIGH EFFECTIVENESS AND LARGE SHARE OF INTRAVENOUS PRODUCTS TO SUPPORT MARKET GROWTH
11.3 SUBCUTANEOUS ROUTE
11.3.1 DEVELOPMENT OF IMPROVED DELIVERY DEVICES TO SUPPORT MARKET GROWTH
11.4 OTHER ROUTES
12 GENE THERAPY MARKET, BY END USER
12.1 INTRODUCTION
12.2 HOSPITALS
12.2.1 GROWING DEMAND FOR ADVANCED THERAPIES TO BOOST MARKET
12.3 SPECIALTY CENTERS
12.3.1 ADVANCEMENTS IN GENE THERAPY TECHNOLOGIES TO SUPPORT MARKET GROWTH
12.4 OTHER END USERS
13 GENE THERAPY MARKET, BY REGION
13.1 INTRODUCTION
13.2 NORTH AMERICA
13.2.1 NORTH AMERICA: MACROECONOMIC ANALYSIS
13.2.2 US
13.2.2.1 US to dominate North American market during forecast period
13.2.3 CANADA
13.2.3.1 Government support for expanding manufacturing facilities to propel market growth
13.3 EUROPE
13.3.1 EUROPE: MACROECONOMIC ANALYSIS
13.3.2 GERMANY
13.3.2.1 Growing pharmaceutical R&D and manufacturing to drive market
13.3.3 UK
13.3.3.1 Strong government support to propel market growth
13.3.4 FRANCE
13.3.4.1 Government investment in pharmaceutical industry to drive growth
13.3.5 ITALY
13.3.5.1 Initiatives for gene therapy development to drive growth
13.3.6 SPAIN
13.3.6.1 Expansion of biomanufacturing facilities to support market growth
13.3.7 SWITZERLAND
13.3.7.1 Presence of key pharmaceutical and biopharmaceutical companies to support market growth
13.3.8 NETHERLANDS
13.3.8.1 Growing awareness and strong focus on pharmaceutical R&D to support market growth
13.3.9 REST OF EUROPE
13.4 ASIA PACIFIC
13.4.1 ASIA PACIFIC: MACROECONOMIC ANALYSIS
13.4.2 CHINA
13.4.2.1 China to dominate Asia Pacific market during forecast period
13.4.3 JAPAN
13.4.3.1 Increasing initiatives supporting gene therapy adoption to propel market growth
13.4.4 INDIA
13.4.4.1 Favorable scenario for foreign direct investment to favor market growth
13.4.5 AUSTRALIA
13.4.5.1 Increasing demand for innovative therapies to propel market
13.4.6 SOUTH KOREA
13.4.6.1 Increased export of drugs to support market growth
13.4.7 THAILAND
13.4.7.1 Favorable government policies to propel adoption of advanced therapies
13.4.8 REST OF ASIA PACIFIC
13.5 LATIN AMERICA
13.5.1 LATIN AMERICA: MACROECONOMIC ANALYSIS
13.5.2 BRAZIL
13.5.2.1 Brazil to dominate LATAM market during forecast period
13.5.3 MEXICO
13.5.3.1 Rising demand for chronic disease treatment to support market growth
13.5.4 REST OF LATIN AMERICA
13.6 MIDDLE EAST
13.6.1 MIDDLE EAST: MACROECONOMIC ANALYSIS
13.6.2 GCC COUNTRIES
13.6.2.1 Saudi Arabia
13.6.2.1.1 Growing healthcare expenditure to boost market growth
13.6.2.2 UAE
13.6.2.2.1 Growing focus on genetic medicine development projects to drive market
13.6.2.3 Rest of GCC Countries
13.6.3 REST OF MIDDLE EAST
13.7 AFRICA
13.7.1 HIGH GROWTH POTENTIAL OF AFRICAN MARKETS TO ATTRACT KEY PLAYERS
13.7.2 AFRICA: MACROECONOMIC ANALYSIS
14 COMPETITIVE LANDSCAPE
14.1 OVERVIEW
14.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2022–2024
14.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN GENE THERAPY MARKET, 2022?2024
14.3 REVENUE ANALYSIS, 2021–2023
14.4 MARKET SHARE ANALYSIS, 2023
14.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
14.5.1 STARS
14.5.2 EMERGING LEADERS
14.5.3 PERVASIVE PLAYERS
14.5.4 PARTICIPANTS
14.5.5 COMPETITIVE BENCHMARKING: KEY PLAYERS, 2023
14.5.5.1 Company footprint
14.5.5.2 Region footprint
14.5.5.3 Therapy type footprint
14.5.5.4 Therapeutic area footprint
14.5.5.5 Route of administration footprint
14.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
14.6.1 PROGRESSIVE COMPANIES
14.6.2 RESPONSIVE COMPANIES
14.6.3 DYNAMIC COMPANIES
14.6.4 STARTING BLOCKS
14.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
14.6.5.1 Detailed list of key startups/SMEs
14.6.5.2 Competitive benchmarking of key startups/SMEs
14.7 VALUATION & FINANCIAL METRICS
14.7.1 FINANCIAL METRICS
14.7.2 COMPANY VALUATION
14.8 BRAND/PRODUCT COMPARISON
14.9 COMPETITIVE SCENARIO
14.9.1 PRODUCT APPROVALS
14.9.2 DEALS
14.9.3 EXPANSIONS
15 COMPANY PROFILES
15.1 INTRODUCTION
15.2 KEY PLAYERS
15.2.1 BIOGEN INC.
15.2.1.1 Business overview
15.2.1.2 Products offered
15.2.1.3 Recent developments
15.2.1.3.1 Deals
15.2.1.4 MnM view
15.2.1.4.1 Key strengths
15.2.1.4.2 Strategic choices
15.2.1.4.3 Weaknesses and competitive threats
15.2.2 NOVARTIS AG
15.2.2.1 Business overview
15.2.2.2 Products offered
15.2.2.3 Recent developments
15.2.2.3.1 Deals
15.2.2.3.2 Expansions
15.2.2.3.3 Other developments
15.2.2.4 MnM view
15.2.2.4.1 Key strengths
15.2.2.4.2 Strategic choices
15.2.2.4.3 Weaknesses and competitive threats
15.2.3 ALNYLAM PHARMACEUTICALS, INC.
15.2.3.1 Business overview
15.2.3.2 Products offered
15.2.3.3 Recent developments
15.2.3.3.1 Product approvals
15.2.3.3.2 Deals
15.2.3.3.3 Other developments
15.2.3.4 MnM view
15.2.3.4.1 Key strengths
15.2.3.4.2 Strategic choices
15.2.3.4.3 Weaknesses and competitive threats
15.2.4 SAREPTA THERAPEUTICS, INC.
15.2.4.1 Business overview
15.2.4.2 Products offered
15.2.4.3 Recent developments
15.2.4.3.1 Product approvals
15.2.4.3.2 Deals
15.2.4.4 MnM view
15.2.4.4.1 Key strengths
15.2.4.4.2 Strategic choices
15.2.4.4.3 Weaknesses and competitive threats
15.2.5 JAZZ PHARMACEUTICALS PLC
15.2.5.1 Business overview
15.2.5.2 Products offered
15.2.5.3 Recent developments
15.2.5.3.1 Expansions
15.2.5.4 MnM view
15.2.5.4.1 Key strengths
15.2.5.4.2 Strategic choices
15.2.5.4.3 Weaknesses and competitive threats
15.2.6 FERRING B.V.
15.2.6.1 Business overview
15.2.6.2 Products offered
15.2.6.3 Recent developments
15.2.6.3.1 Product approvals
15.2.6.3.2 Deals
15.2.6.3.3 Expansions
15.2.7 PFIZER INC.
15.2.7.1 Business overview
15.2.7.2 Products offered
15.2.7.3 Recent developments
15.2.7.3.1 Product approvals
15.2.7.3.2 Deals
15.2.8 AMGEN, INC.
15.2.8.1 Business overview
15.2.8.2 Products offered
15.2.8.3 Recent developments
15.2.8.3.1 Deals
15.2.8.3.2 Expansions
15.2.9 JOHNSON & JOHNSON SERVICES, INC.
15.2.9.1 Business overview
15.2.9.2 Products offered
15.2.9.3 Recent developments
15.2.9.3.1 Deals
15.2.9.3.2 Other developments
15.2.10 DAIICHI SANKYO COMPANY, LIMITED.
15.2.10.1 Business overview
15.2.10.2 Products offered
15.2.11 BIOMARIN PHARMACEUTICAL INC.
15.2.11.1 Business overview
15.2.11.2 Products offered
15.2.11.3 Recent developments
15.2.11.3.1 Product approvals
15.2.11.3.2 Expansions
15.2.12 KYOWA KIRIN CO., LTD.
15.2.12.1 Business overview
15.2.12.2 Products offered
15.2.12.3 Recent developments
15.2.12.3.1 Product approvals
15.2.12.3.2 Deals
15.2.13 NIPPON SHINYAKU CO., LTD.
15.2.13.1 Business overview
15.2.13.2 Products offered
15.2.13.3 Recent developments
15.2.13.3.1 Deals
15.2.14 PTC THERAPEUTICS
15.2.14.1 Business overview
15.2.14.2 Products offered
15.2.14.3 Recent developments
15.2.14.3.1 Product approvals
15.2.15 UNIQURE NV.
15.2.15.1 Business overview
15.2.15.2 Products offered
15.2.15.3 Recent developments
15.2.15.3.1 Deals
15.3 OTHER PLAYERS
15.3.1 JUVENTAS CELL THERAPY LTD.
15.3.2 CRISPR THERAPEUTICS
15.3.3 BLUEBIRD BIO, INC.
15.3.4 KRYSTAL BIOTECH, INC.
15.3.5 SHANGHAI SUNWAY BIOTECH CO., LTD.
15.3.6 JW (CAYMAN) THERAPEUTICS CO. LTD
15.3.7 IASO BIOTECHNOLOGY
15.3.8 CARSGEN THERAPEUTICS HOLDINGS LIMITED
15.3.9 ADAPTIMMUNE
15.3.10 SIBIONO GENETECH CO. LTD.
15.3.11 ULTRAGENYX PHARMACEUTICAL INC.
16 APPENDIX
16.1 DISCUSSION GUIDE
16.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
16.3 CUSTOMIZATION OPTIONS
16.4 RELATED REPORTS
16.5 AUTHOR DETAILS
